ACE Inhibitors with Thiazides Drugs Market - Forecast(2022 - 2027)

Report Code: HCR 1459 Report Format: PDF + Excel

ACE Inhibitors with Thiazides Drugs Market Overview

ACE Inhibitors with Thiazides Drugs Market size is estimated to reach $8.7 billion by 2027, growing at a CAGR of 2.4% during the forecast period 2022-2027. Angiotensin-converting-enzyme (ACE) inhibitors can be delineated as a class of drugs normally taken into account or prescribed by medical practitioners for the treatment of various heart problems and blood-associated complications like unstable blood pressure. Medical studies suggest that the presence of more amount of salt such as sodium in the blood tends to draw excess water and consequently augment the blood pressure levels. This whole mechanism starts when ACE alters a blood enzyme called (angiotensin enzyme 1) into (angiotensin enzyme 2) which routinely narrows the size of the blood vessels and releases blood pressure-increasing enzymes. Therefore, ACE inhibitors work by impeding the entire process of conversion. Fosinopril, captopril, quinapril, and others are primary examples of ACE inhibitors. In addition to that, thiazides (Indapamide and hydrochlorothiazide) are FDA-approved diuresis promoting medications which help in HBT. The ACE inhibitors with thiazides drugs market outlook are exceptionally enchanting as the complications like heart attack are merging as leading cause of deaths globally. Moreover, growing stress and depression due to eventful lifestyles, poor digestion, ascending old-age population, and growing research and developmental activities are the factors set to drive the growth of the ACE Inhibitors with Thiazides Drugs Market for the period 2022-2027.

Report Coverage

The report: “ACE Inhibitors with Thiazides Drugs Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the ACE Inhibitors with Thiazides Drugs Market.

By Product Type: hydrochlorothiazide/Fosinopril, hydrochlorothiazide/Captopril, Benazepril, Quinapril, and others.
By Administration Mode: Oral (Liquid and tablets) and Injections.
By Applications: Migraine, Skin ailments, Coronary artery hitches, Kidney associated complications, Heart problems, High blood pressure, Diabetes, and others.
By Distribution Channel: Offline channels (Hospital Pharmacies, Retail pharmacies, Drug stores) and Online platforms.
By Geography: North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America) and Rest of World (the Middle East and Africa).

Key Takeaways

  • Geographically, the North America ACE Inhibitors with Thiazides Drugs Market accounted for the highest revenue share in 2021. However, Asia-Pacific is poised to dominate the market over the period 2022-2027.
  • Bourgeoning research, ascending health responsiveness among people, and proliferating prevalence of chronic maladies and blood-associated complications such as hypertension and diabetes are said to be preeminent drivers driving the growth of ACE Inhibitors with Thiazides Drugs Market. Side effects and various uncertainties accompanied by effectiveness are said to reduce the market growth.
  • Detailed analysis of the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the ACE Inhibitors with Thiazides Drugs Market report.

ACE Inhibitors with Thiazides Drugs Market Share, By Region (%) in 2021

ACE Inhibitors with Thiazides Drugs Market

For more details on this report - Request for Sample

ACE Inhibitors with Thiazides Drugs Market Segment Analysis-By Application

The ACE Inhibitors with Thiazides Drugs Market based on the application type can be further segmented into kidney-associated complications, heart problems, high blood pressure, diabetes, and others. The high blood pressure segment held the largest share in 2021. The growth is owing to the widescale pervasiveness of complications like HBT. COVID-19 has adversely impacted the mental health of millions of people around the globe as people have to bear many traumatic events such as quarantines, job loss, death of loved ones, and many more all at once. On the other hand, spiraling alcohol consumption and smoking trends, proliferating complications of diabetes, poor ingestion (salt-rich and fast food), and widescale obesity due to sedentary habits bound with modern lifestyles are major factors justifying the growth of the market. However, diabetes and heart attack segments are estimated to be the fastest-growing with a CAGR of 3.5% over the forecast period 2022-2027. This growth is owing to the rising incidences of deaths associated with heart attacks and diabetes. According to a report, a heart attack is the deadliest cardiovascular illness responsible for millions of deaths every year.

ACE Inhibitors with Thiazides Drugs Market Segment Analysis-By Distribution Channel

The ACE Inhibitors with Thiazides Drugs Market based on distribution channels can be further segmented into offline channels (hospital pharmacies, retail pharmacies, and drug stores) and online platforms. The offline segment held the largest share in 2021. The growth is owing to the wide-ranging presence of offline channels like retail and hospital pharmacies in deprived areas. Due to squalid conditions, the growth opportunities for online platforms are still limited in the countryside. Consequently, people rely upon in-person purchases. Moreover, retail pharmacies extend the benefits of purchasing medications without a prior prescription. However, the online platforms segment is estimated to be the fastest-growing with a CAGR of 3.8% over the forecast period 2022-2027. This growth is owing to refining infrastructure, especially in developing countries like India and China. Better infrastructure ensures obstruction-free functioning of online platforms while delivering the ordered products. On another hand, sweeping digitalization, heightened threat of communicable diseases, and 24/7 access to fast internet are the factors ensuring steady growth.

ACE Inhibitors with Thiazides Drugs Market Segment Analysis-By Geography

The ACE Inhibitors with Thiazides Drugs Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share with 40% of the overall market in 2021. The growth in this segment is owing to the factors such as the heavy presence of obesity and diabetes due to the ultra-modern lifestyles of people. Unlike several low-income and middle-income countries in Africa and Asia, nearly little to no amount of work is accomplished manually in countries like Canada and the US as a result several complications have come to the foreground. On another hand, the presence of top-notch pharmaceutical players like Pfizer, high health cognizance among people, and a sound network of both offline and online platforms are the prominent explanations behind the market hold. However, Asia-Pacific is expected to be the fastest-growing segment over the forecast period 2022-2027. This growth is owing to mind-numbing pharmaceutical production in India and China and the budding geriatric population in countries like China and Japan. Moreover, improving the quality of lifestyles and growing western influence have dragged people toward unhealthy habits like RTE foods, alcohol consumption, and too much dependence on machines have their fair share is driving the demand for ACE inhibitors with thiazides drugs market in the said region.

ACE Inhibitors with Thiazides Drugs Market Drivers

Growing heart diseases is Anticipated to Boost Product Demand. 

Prolonged sittings, stress, alcohol, smoking, excessive consumption of salt-rich food, and lower water intake are some of the preeminent factors driving the growth of ACE inhibitors with thiazides drugs market. It should not come as a surprise that the COVID-19 outbreak has driven millions of people into depression. People who somehow bear the trauma of pain inflicted by the pandemic have developed or are more likely to develop complications like HBT, whereas, others who remained unsuccessful to cope with it have lost or intentionally taken their lives. For instance, a recent report published in 2022 suggests that, due to unemployment and inability to repay debt more than 25,000 people who were residents of India had committed suicide in 2018-2020. On another hand, rising diabetes cases are acting as a stimulus to the respective market. For instance, 10% of the world population is afflicted with diabetes and this blood sugar complication was accountable for more than $900 billion of health expenditure throughout the globe in 2021.

Old-age population and rising pharmaceutical production in developing countries are Expected to Boost Product Demand.

30 percent of Japan’s population is old-age and the figure is likely to reach 37-38 percent by 2060. Similarly, approximately 19 percent (263-265 million people) of the Chinese population falls under the category of old-age people (>65 years). Besides, as the world is reeling under the weight of such catastrophic events, pharmaceutical companies all around the globe have heightened their drug production and research and development activities. Besides, the government of various countries is doing whatever is in their power to curb or better deal with health complications standing in front of the world and posing an existential threat to humanity. In an attempt to lead the world in R&D and pharma production developing nations like India and China are stimulating their spending and alluring businesses with lucrative schemes.

ACE Inhibitors with Thiazides Drugs Market Challenges

Uncertainty regarding effectiveness and side effects is Anticipated to Hamper Market Growth.

ACE inhibitors with thiazide drugs may lead to various health complications like hyperkalemia, dizziness, nausea, suffocation, headache, and even loss of taste in several cases. According to a Journal published in 2020 by the JAMA network, edema was prevalent among 0.5% of participants receiving ACE inhibitors. Therefore, the emergence of such complications may drive people away from the intake of such drugs which will automatically hamper the steady growth of ACE inhibitors in the thiazides drugs market. On another hand, uncertainties regarding the usefulness or effectiveness of such drugs are too anticipated to curb the growth of the aforementioned market.

ACE Inhibitors with Thiazides Drugs Industry Outlook:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the ACE Inhibitors with Thiazides Drugs Market. Key companies in this market include:

  1. Sanofi S.A.
  2. Pfizer Inc.
  3. Novartis Internation AG
  4. Abbott Laboratories
  5. Johnson & Johnson
  6. Merck &Co.
  7. AbbVie
  8. AstraZeneca PLC.
  9. Mylan N.V.
  10. UCB SA

Recent Developments

  • On December 22, 2021, Paris, France-based well-known healthcare company “Sanofi” announced the successful acquisition of California, United States-based biopharmaceutical company “Amunix.” Sanofi has paid $1 billion in order to bring the acquisition to a close. Moreover, the company has pledged to confer $225 million on the achievement/completion of future projects.
  • On May 8, 2020, Illinois, United States-based biopharmaceutical company “AbbVie” announced that the company has successfully acquired an American-Irish pharmaceutical company “Allergan.” AbbVie made a mind-numbing payment of $63 billion ($193.23 per share) dollars in order to wrap up the merger process. The transaction has strengthened the immunology business of AbbVie.
  • On January 6, 2020, Basel, Switzerland-based renowned pharmaceutical manufacturer “Novartis AG” publicized the successful acquisition of New Jersey, United States-based “The Medicine Company”, a firm that deals in acute care treatments. The transaction adds “Inclisiran” a cholesterol controlling therapy to Novartis's portfolio. Moreover. A jaw-dropping payment of $9.7 billion was made to conclude the process.

Relevant Links:

Report Code: HCR 0263

Report Code: HCR 0574

Report Code: HCR 0217 

For more Lifesciences and Healthcare related reports, please click here

1. ACE Inhibitors with Thiazides Drugs Market Overview
    1.1 Definitions and Scope
2. ACE Inhibitors with Thiazides Drugs Market - Executive Summary
3. ACE Inhibitors with Thiazides Drugs Market– Market Landscape
    3.1 Company Benchmarking- Key Companies
    3.2 Key Company Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis-Global
    3.5 Pricing Analysis (Comparison of General Price Offerings in the Market)
4. ACE Inhibitors with Thiazides Drugs Market– Startup Company Scenario (Premium)
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5. ACE Inhibitors with Thiazides Drugs Market– Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Scenario
    5.2 New Business and Ease of Doing business index-Global
    5.3 Case Studies of Successful Ventures
6. ACE Inhibitors with Thiazides Drugs Market- Market Forces
    6.1 Market Drivers
    6.2 Market Constraints
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. ACE Inhibitors with Thiazides Drugs Market– By Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle Analysis
8. ACE Inhibitors with Thiazides Drugs Market - By Product Type (Market Size –$Million/$Billion) 
    8.1 Hydrochlorothiazide/Fosinopril
    8.2 Hydrochlorothiazide/Captopril
    8.3 Hydrochlorothiazide/Benazepril
    8.4 Hydrochlorothiazide/Quinapril
    8.5 Others.
9. ACE Inhibitors with Thiazides Drugs Market - By Administration Mode (Market Size –$Million/$Billion) 
    9.1 Oral (Liquid and tablets)
    9.2 Injections
10. ACE Inhibitors with Thiazides Drugs Market – By Applications (Market Size –$Million/$Billion) 
    10.1 Migraine
    10.2 Skin ailments
    10.3 Coronary artery hitches
    10.4 Kidney associated complications
    10.5 Heart problems
    10.6 High blood pressure
    10.7 Diabetes
    10.8 Others
11. ACE Inhibitors with Thiazides Drugs Market – By Distribution Channel (Market Size –$Million/$Billion) 
    11.1 Offline channels (Hospital Pharmacies, Retail pharmacies, Drug stores)
    11.2 Online platform
12. ACE Inhibitors with Thiazides Drugs Market- By Geography (Market Size -$Million/Billion)
    12.1 North America
        12.1.1 U.S
        12.1.2 Canada
        12.1.3 Mexico 
    12.2 Europe
        12.2.1 Germany
        12.2.2 France
        12.2.3 UK
        12.2.4 Italy
        12.2.5 Spain
        12.2.6 Russia
        12.2.7 Rest of Europe
    12.3 Asia-Pacific
        12.3.1 China
        12.3.2 Japan
        12.3.3 South Korea
        12.3.4 India
        12.3.5 Australia & New Zealand
        12.3.6 Rest of Asia-Pacific 
    12.4 South America
        12.4.1 Brazil
        12.4.2 Argentina
        12.4.3 Chile
        12.4.4 Colombia
        12.4.5 Rest of South America
    12.5 Rest of the World
        12.5.1 Middle East
        12.5.2 Africa
13. ACE Inhibitors with Thiazides Drugs Market- Market Entropy
    13.1 New product launches
    13.2 M&A's, collaborations, JVs and partnerships
14. ACE Inhibitors with Thiazides Drugs Market– Industry Competition Landscape (Premium)
    14.1 Market Share Analysis
        14.1.1 Global Market Share – Key Companies
        14.1.2 Market Share by Region – Key Companies
        14.1.3 Market Share by Countries – Key Companies
    14.2 Competition Matrix
    14.3 Best Practices for Companies
15. ACE Inhibitors with Thiazides Drugs Market– Key Company List by Country Premium (Premium)
16. ACE Inhibitors with Thiazides Drugs Market- Company Analysis
    16.1 Company 1
    16.2 Company 2
    16.3 Company 3
    16.4 Company 4
    16.5 Company 5
    16.6 Company 6
    16.7 Company 7
    16.8 Company 8
    16.9 Company 9
    16.10 Company 10
"*Financials would be provided on a best-efforts basis for private companies"